Zelluna ASA Secures Funding for Innovative Cancer Therapy
Zelluna ASA has successfully completed a private placement and retail offering, raising NOK 58 million to move forward with ZI-MA4-1, the first "off-the-shelf" TCR-NK therapy for treating cancer.
This initiative has garnered strong backing from shareholders, management, and board members, all of whom bring extensive experience in life sciences and cell therapies.
Zelluna ASA, a pioneering company in allogeneic T Cell Receptor based Natural Killer (TCR-NK) cells, is ready to embark on clinical trials to bring a novel treatment to solid cancer patients.
On a designated date, the company will hold a webcast to present its quarterly results and provide insights into the private placement process, ensuring that stakeholders are kept informed.
The successful financing indicates robust confidence in Zelluna's TCR-NK platform, reflecting the progressive vision for allogeneic cell therapies. This funding milestone not only illustrates trust from investors but also emphasizes the potential to enhance and innovate cancer treatments.
Key objectives of this funding include initiating clinical trials for ZI-MA4-1, generating crucial patient data, and broadening the company's developmental pipeline. The investment reflects an increased desire within the healthcare market for scalable cell therapies.
According to the CEO of Zelluna, Namir Hassan, this funding campaign represents a transformative stage for the company. It equips Zelluna with necessary resources to begin treating patients with its pioneering therapy and recognizes the significant long-term potential for late-stage cancer patients.
Investor Confidence and Financial Details
Anders Tuv, the Chairman of the Board, also expressed gratitude for the ongoing support from both existing and new investors, pointing out this as a testament to Zelluna's commitment to pioneering in cell therapy innovation.
The private placement was concluded successfully, with 5,500,000 shares allocated at a subscription price of NOK 10 per share, amounting to gross proceeds of NOK 55 million, while an additional 315,639 shares were allocated through a retail offering, adding NOK 3.16 million to the total.
Overall, the proceeds from these funding efforts will directly support the company's ambitious plans, further enhancing its pipeline and overall operational capabilities.
Shareholder Structure and Future Plans
Multiple shareholders, including international investment groups and management insiders, have committed to this funding round, showcasing a blend of institutional and personal investments. Significant allocations include:
- Oxford Investors: NOK 24.8 million
- Sundt AS: NOK 10 million
- Gjelsten Holding AS: NOK 5 million
- Management & Board participation: NOK 1.2 million from CEO Namir Hassan alone.
The shares from the private placement were distributed in two tranches. The initial tranche was approved, while the second tranche awaits upcoming General Meetings. Depending on the approval date, allocations in the second tranche are anticipated to be delivered shortly after.
There's also potential for a subsequent offering aimed at existing shareholders which could provide further opportunities for engagement and investment.
The Path Forward for Zelluna ASA
Looking ahead, Zelluna ASA is poised to establish itself as a frontrunner in the next wave of cancer therapies. Its commitment to developing effective and accessible treatments aligns perfectly with growing market demands.
The company is led by a highly knowledgeable management team that brings together rich experiences ranging from research and development to clinical application, all geared towards overcoming the challenges posed by traditional cancer treatments.
In summary, Zelluna ASA's journey from a promising concept to a clinical reality seems promising. This new round of funding is anticipated not only to enhance the company's research and development capabilities but also to usher in a new chapter of hope for patients facing the challenges of advanced solid cancers.
Frequently Asked Questions
What is Zelluna ASA's primary product?
Zelluna ASA's main product is ZI-MA4-1, an innovative “off-the-shelf” TCR-NK therapy designed for treating solid tumors.
How much capital did Zelluna ASA raise?
The company raised NOK 58 million through a combination of a private placement and a retail offering.
What will the funds be used for?
The proceeds will support the initiation of Phase I clinical trials, pipeline development, and general corporate purposes.
Who are the notable investors in this funding round?
Investors include Oxford Investors and key management and board members, reflecting diverse support for Zelluna’s mission.
How does Zelluna plan to engage with shareholders moving forward?
The company is considering a subsequent offering directed at existing shareholders to mitigate dilution effects and enhance shareholder involvement.
